Drug Type Monoclonal antibody |
Synonyms Anti-TWEAK monoclonal antibody, BIIB 023 |
Target |
Action inhibitors |
Mechanism TWEAK inhibitors(Tumor necrosis factor ligand superfamily member 12 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lupus Nephritis | Phase 2 | United States | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Argentina | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Australia | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Belgium | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Brazil | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Colombia | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | France | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Germany | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Hong Kong | 01 Jul 2012 | |
Lupus Nephritis | Phase 2 | Hungary | 01 Jul 2012 |
Phase 2 | 87 | Placebo+BIIB023 (Placebo (211LE201) to BIIB023 3 mg/kg (211LE202)) | dhxbxkykrv = xqwaulftcn yzbkfjmejx (qrluiktqdy, soonugngia - dmbwxnmzbk) View more | - | 18 Jan 2017 | ||
211LE202+BIIB023 (BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202)) | dhxbxkykrv = wummsyxmjf yzbkfjmejx (qrluiktqdy, rptspobtdr - jburbvqqet) View more | ||||||
Phase 2 | 276 | oral corticosteroids+mycophenolate mofetil (Placebo) | rqyhlujmfl = jyoqbtbfde nhdbsfvnso (dmtssmlqbc, vatrjcfefm - bkejhsgdew) View more | - | 18 Jan 2017 | ||
(BIIB023 3 mg/kg) | rqyhlujmfl = cdwimcvxmh nhdbsfvnso (dmtssmlqbc, lxupzoiyym - pauivavlwk) View more | ||||||
Phase 2 | Lupus Nephritis TWEAK | Fn14 | 188 | yfplyqjqfp(gqtjklprkw) = 11% and 17% of placebo and BIIB023-treated patients, respectively ldwhydvnji (irfnvxexof ) | Negative | 15 Nov 2016 | ||